Literature DB >> 15972540

Inhibition of proteolytic activity of a chlamydial proteasome/protease-like activity factor by antibodies from humans infected with Chlamydia trachomatis.

Jyotika Sharma1, Feng Dong, Mustak Pirbhai, Guangming Zhong.   

Abstract

We have previously shown that individuals infected with Chlamydia trachomatis can develop a robust antibody response to a chlamydia-secreted protein (designated chlamydial proteasome/protease-like activity factor [CPAF]). We now report that sera collected from these infected individuals neutralized the proteolytic activity of CPAF. Depletion of the serum sample with CPAF proteins to remove the CPAF-specific antibodies effectively blocked the neutralization, whereas similar depletion with the HSP60 proteins failed to do so. We further demonstrated that the CPAF central region covering residues 200 to 338 was predominantly recognized by the human neutralization antibodies. The significance of the CPAF neutralization antibodies generated in chlamydia-infected individuals is discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15972540      PMCID: PMC1168553          DOI: 10.1128/IAI.73.7.4414-4419.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

Review 1.  The cellular paradigm of chlamydial pathogenesis.

Authors:  Richard S Stephens
Journal:  Trends Microbiol       Date:  2003-01       Impact factor: 17.079

2.  NF-kappa B activation is not required for Chlamydia trachomatis inhibition of host epithelial cell apoptosis.

Authors:  Yangming Xiao; Youmin Zhong; Heng Su; Zhiguang Zhou; Paul Chiao; Guangming Zhong
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

3.  Chlamydia-infected cells continue to undergo mitosis and resist induction of apoptosis.

Authors:  Whitney Greene; Yangming Xiao; Yanqing Huang; Grant McClarty; Guangming Zhong
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

4.  Inhibition of host cell cytokinesis by Chlamydia trachomatis infection.

Authors:  Whitney Greene; Guangming Zhong
Journal:  J Infect       Date:  2003-07       Impact factor: 6.072

5.  Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection.

Authors:  H Su; M Parnell; H D Caldwell
Journal:  Vaccine       Date:  1995-08       Impact factor: 3.641

6.  Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix.

Authors:  R C Brunham; C C Kuo; L Cles; K K Holmes
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

7.  Intramolecular dimerization is required for the chlamydia-secreted protease CPAF to degrade host transcriptional factors.

Authors:  Feng Dong; Jyotika Sharma; Yanming Xiao; Youmin Zhong; Guangming Zhong
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

8.  Cleavage-dependent activation of a chlamydia-secreted protease.

Authors:  Feng Dong; Mustak Pirbhai; Youmin Zhong; Guangming Zhong
Journal:  Mol Microbiol       Date:  2004-06       Impact factor: 3.501

9.  Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells.

Authors:  G Zhong; L Liu; T Fan; P Fan; H Ji
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

10.  Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors.

Authors:  G Zhong; P Fan; H Ji; F Dong; Y Huang
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

View more
  21 in total

1.  Association of tubal factor infertility with elevated antibodies to Chlamydia trachomatis caseinolytic protease P.

Authors:  Allison K Rodgers; Jie Wang; Yingqian Zhang; Alan Holden; Blake Berryhill; Nicole M Budrys; Robert S Schenken; Guangming Zhong
Journal:  Am J Obstet Gynecol       Date:  2010-11       Impact factor: 8.661

2.  Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.

Authors:  Ashlesh K Murthy; James P Chambers; Patricia A Meier; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

Review 3.  Molecular mechanisms of host-pathogen interactions and their potential for the discovery of new drug targets.

Authors:  Volker Briken
Journal:  Curr Drug Targets       Date:  2008-02       Impact factor: 3.465

4.  A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice.

Authors:  Jie Wang; Lili Chen; Fan Chen; Xiaoyun Zhang; Yingqian Zhang; Joel Baseman; Sondra Perdue; I-Tien Yeh; Rochelle Shain; Martin Holland; Robin Bailey; David Mabey; Ping Yu; Guangming Zhong
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641

Review 5.  Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies.

Authors:  Byron E Batteiger; Fujie Xu; Robert E Johnson; Michael L Rekart
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

6.  Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele.

Authors:  Ashlesh K Murthy; Yu Cong; Cathi Murphey; M Neal Guentzel; Thomas G Forsthuber; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2006-10-02       Impact factor: 3.441

7.  Preparation and evaluation of monoclonal antibodies against chlamydial protease-like activity factor to detect Chlamydia pneumoniae antigen in early pediatric pneumonia.

Authors:  J Zheng; T Ding; Z Chen; H Fang; H Li; H Lu; Y Wu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-03-12       Impact factor: 3.267

8.  Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge.

Authors:  Bharat K R Chaganty; Ashlesh K Murthy; Shankar J Evani; Weidang Li; M Neal Guentzel; James P Chambers; Guangming Zhong; Bernard P Arulanandam
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

9.  Identifying catalytic residues in CPAF, a Chlamydia-secreted protease.

Authors:  Ding Chen; Jijie Chai; P John Hart; Guangming Zhong
Journal:  Arch Biochem Biophys       Date:  2009-05-01       Impact factor: 4.013

10.  Caspase-1 contributes to Chlamydia trachomatis-induced upper urogenital tract inflammatory pathologies without affecting the course of infection.

Authors:  Wen Cheng; Pooja Shivshankar; Zhongyu Li; Lili Chen; I-Tien Yeh; Guangming Zhong
Journal:  Infect Immun       Date:  2007-11-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.